These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36811981)

  • 1. Humira: the first $20 billion drug.
    Gibbons JB; Laber M; Bennett CL
    Am J Manag Care; 2023 Feb; 29(2):78-80. PubMed ID: 36811981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humira: the impending patent battles over adalimumab biosimilars.
    Norman P
    Pharm Pat Anal; 2016 May; 5(3):141-5. PubMed ID: 27087201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
    Coghlan J; He H; Schwendeman AS
    J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
    Storz U
    Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological patent thickets and delayed access to biosimilars, an American problem.
    Goode R; Chao B
    J Law Biosci; 2022; 9(2):lsac022. PubMed ID: 36072417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bringing Humira (Its Price) Down a Peg.
    Ladika S
    Manag Care; 2019 Jan; 28(1):7-8. PubMed ID: 30883314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do pharmaceutical prices rise anticipating branded competition?
    Ellyson AM; Basu A
    Health Econ; 2021 May; 30(5):1070-1081. PubMed ID: 33684255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Biosimilars of Adalimumab.
    Kaushik VV
    J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation.
    Nagar S; Kesselheim AS
    J Law Med Ethics; 2021; 49(4):683-687. PubMed ID: 35006061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 12. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar competition: Early learning.
    Frank RG; Shahzad M; Kesselheim AS; Feldman W
    Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The $5 Billion Hop: Glatiramer Acetate and the US Patent System.
    Patel NG; Kesselheim AS
    J Law Med Ethics; 2022; 50(4):852-856. PubMed ID: 36883396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Wins Designation as a Biosimilar Product to Humira.
    Aschenbrenner DS
    Am J Nurs; 2022 Feb; 122(2):24. PubMed ID: 35085144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.